Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 15/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 14/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.67 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30557833 | 0.81 | TAAR1 (0.61) | HTR2ASLC6A4KCNH2TAAR1ADRA1A | |
| SCHEMBL8747066 | 0.81 | TAAR1 (0.66) | HTR2ASLC6A4KCNH2TAAR1ADRA1A | |
| SCHEMBL10506599 | 0.81 | TAAR1 (0.61) | HTR2ASLC6A4KCNH2TAAR1ADRA1A | |
| SCHEMBL30207828 | 0.81 | TAAR1 (0.66) | HTR2ASLC6A4KCNH2TAAR1ADRA1A | |
| SCHEMBL5837159 | 0.80 | HTR2A (1.00) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL5837154 | 0.80 | SLC6A4 (1.00) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL626051 | 0.80 | TAAR1 (0.73) | HTR2ATAAR1ADRA1ACYP1A2 | |
| SCHEMBL5498728 | 0.77 | ADRA1A (0.56) | HTR2ASLC6A4KCNH2TAAR1ADRA1A | |
| SCHEMBL5837833 | 0.74 | SLC6A4 (1.00) | HTR2ASLC6A4KCNH2 | |
| SCHEMBL15832058 | 0.74 | HTR2A (0.58) | HTR2ASLC6A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050059654-A1 | Method for treatment of depression and anxiety disorders by combination therapy | ARNERIC STEPHEN P (US) | 2005-03-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059654-A1 | Method for treatment of depression and anxiety disorders by combination therapy | SLC6A2, SLC18A2, ADRA2C | HTR2A 16/4885SLC6A4 4/4885KCNH2 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.